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Abstract
Background: Transforming growth factor-b (TGF-b) and matrix metalloproteinases (MMPs) are the multifunctional
factors during diverse physiological and pathological processes including development, wound healing,
proliferation, and cancer metastasis. Both TGF-b and MMPs have been shown to play crucial roles in brain
pathological changes. Thus, we investigated the molecular mechanisms underlying TGF-b1-induced MMP-9
expression in brain astrocytes.
Methods: Rat brain astrocytes (RBA-1) were used. MMP-9 expression was analyzed by gelatin zymography and RT-
PCR. The involvement of signaling molecules including MAPKs and NF-B in the responses was investigated using
pharmacological inhibitors and dominant negative mutants, determined by western blot and gene promoter assay.
The functional activity of MMP-9 was evaluated by cell migration assay.
Results: Here we report that TGF-b1 induces MMP-9 expression and enzymatic activity via a TGF-b receptor-
activated reactive oxygen species (ROS)-dependent signaling pathway. ROS production leads to activation of
extracellular signal-regulated kinase 1/2 (ERK1/2) and c-Jun-N-terminal kinase (JNK) and then activation of the NF-
B transcription factor. Activated NF-B turns on transcription of the MMP-9 gene. The rat MMP-9 promoter,
containing a NF-B cis-binding site, was identified as a crucial domain linking to TGF-b1 action.
Conclusions: Collectively, in RBA-1 cells, activation of ERK1/2- and JNK-NF-B cascades by a ROS-dependent
manner is essential for MMP-9 up-regulation/activation and cell migration induced by TGF-b1. These findings
indicate a new regulatory pathway of TGF-b1 in regulating expression of MMP-9 in brain astrocytes, which is
involved in physiological and pathological tissue remodeling of central nervous system.
Background
Matrix metalloproteinases (MMPs) are a large family of
zinc-dependent endopeptidases that play an important
role in the turnover of extracellular matrix (ECM) and
function in physiological and pathological processes [1].
In the central nervous system (CNS), MMPs, and
MMP-9 especially, are implicated in development, mor-
phogenesis, wounding healing, neurite outgrowth, and
immune cell migration [2]. In addition, they also partici-
pate in the pathogenesis of several CNS diseases such as
stroke, Alzheimer’s disease, neuroinflammation, and
malignant glioma [3]. Among members of the MMP
family, MMP-9 has been shown to be elevated in var-
ious brain disorders [4-6]. Moreover, several pro-inflam-
matory mediators such as interleukin-1b (IL-1b),
lipopolysaccharide, bradykinin (BK), and oxidized low-
density lipoprotein (oxLDL) can induce MMP-9 expres-
sion and activity in cultured rat astrocytes [7-10], indi-
cating that the expression and activation of MMP-9 may
be regulated during brain injuries and inflammation.
Transforming growth factor-b (TGF-b) is a multifunc-
tional cytokine that regulates a broad diversity of phy-
siological and pathological processes, including tissue
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any medium, provided the original work is properly cited.wound healing, inflammation, cell proliferation, differen-
tiation, migration, and extracellualr matrix (ECM) synth-
esis [11-13]. Accordingly, TGF-b family members play
an important role in early embryogenesis and in the
homeostasis of adult tissues. However, several lines of
evidence show that lack of coordination of TGF-b-
dependent signaling often leads to a number of human
diseases, including fibrosis [14,15], cancer [16,17], and
autoimmune diseases [18]. Moreover, TGF-b is a key
immune system modulator, TGF-b1 especially, that may
have both pro- and anti-inflammatory effects in immune
system depending on the cell type (11-13). Within the
CNS, all three isoforms of TGF-bs family, i.e.T G F - b1,
-b2, and -b3, are produced by both glial and neural cells
[19]. Previous reports have suggested a relationship
between increased TGF-b1 levels and cerebral ischemic
injury [20,21]. Following CNS injury, elevated TGF-b
levels in astrocytes has beenp r o v e nt ob ea s s o c i a t e d
with astrocytic scar formation [22]. Emerging evidence
has also demonstrated that TGF-b1 is a crucial mediator
in the pathogenesis of several CNS disorders, such as in
organization of glial scars in response to injury and in
several neurodegenerative disorders [11,15,23].
TGF-bs binds to two serine/threonine kinase receptors
which consist of TGF-bRI and TGF-bRII. When a ligand
binds, TGF-bRII phosphorylates TGF-bRI and activates
Smad-dependent intracellular signaling pathways and
thus leads to expression of several genes [24-26]. In
addition to activation of Smad-dependent pathways,
TGF-b can affect several signal transduction pathways
in a Smad-independent manner, such as mitogen-acti-
vated protein kinases (MAPKs), including extracellular-
signal-related protein kinase (ERK1/2), p38 MAPK, and
c-Jun N-terminal kinase (JNK) [12,25,27]. In human gin-
gival and skin fibroblasts, both p38 MAPK and Smad3
cooperate in regulating TGF-b-induced MMP-13
expression, whereas ERK1/2 cooperates with Smad3 in
regulating connective tissue growth factor expression
[25,28,29]. Recently, increasing evidence has attributed
the cellular damage in neurodegenerative disorders to
oxidative stress that leads to generation of reactive oxy-
gen species (ROS) that are responsible for brain inflam-
matory disorders and that have deleterious effects
during CNS pathogenic processes [30-32]. TGF-b can
stimulate ROS production, which participates in the
expression of diverse genes, such as those for MMPs, in
the processes of several human diseases like lung fibro-
sis [33,34]. However, very little information is available
concerning the intracellular pathways involved in the
effects of TGF-b1 in brain cells.
Recently, several studies have shown that TGF-b1c a n
up-regulate MMP-9 expression and activity in several
cell types such as human skin [35] and corneal epithelial
cells [36], implying a crucial role of TGF-b1i nt h e
regulation of MMP-9 in tissuer e m o d e l i n ga n dw o u n d
healing during physiological and pathological processes.
The MMP-9 expression is regulated by various mechan-
isms such as transcriptional and translational regulation
in MMP-9 synthesis. The promoter of MMP-9 has been
characterized to possess a series of functional enhancer
element-binding sites, such as nuclear factor-B
(NF-B) and activator protein-1 (AP-1), but not in
MMP-2 promoter [37,38]. In RBA-1 cells, our previous
studies have demonstrated that IL-1b and BK can up-
regulate MMP-9 expression via activation of NF-B
[39,40]. However, the possibility of MAPKs and NF-B
activation and their roles in MMP-9 up-regulation and
cellular function (migration) induced by TGF-b1i n
astrocytes (RBA-1 cells) are poorly defined.
In this study, we investigated the molecular mechan-
isms and the functional responses underlying TGF-b1-
induced MMP-9 expression in RBA-1 cells. These find-
ings indicate that TGF-b1-induced MMP-9 expression
via TGF-b receptors is mediated through a ROS-depen-
dent activation of ERK1/2, JNK1/2, and NF-B pathway,
finally leading to cell migration in RBA-1 cells. These
results suggest that TGF-b1-induced astrocytic MMP-9
up-regulation might play a key role in physiological and
pathological brain tissue remodeling such as wound
healing and scar formation.
Methods
Materials
DMEM/F-12 medium, fetal bovine serum (FBS), and
TRIzol were from Invitrogen (Carlsbad, CA, USA).
Hybond C membrane and enhanced chemiluminescence
(ECL) western blotting detection system were from GE
Healthcare Biosciences (Buckinghamshire, UK). Phos-
pho-(Thr
202/Tyr
204)-ERK1/2, phospho-(Ser
176/180)-JNK1/
2, and phospho-(Ser
536)-p65 antibody kits were from
Cell Signaling (Danver, MA, USA). GAPDH antibody
was from Biogenesis (Boumemouth, UK). All primary
antibodies were diluted at 1:1000 in phosphate-buffered
saline (PBS) with 1% BSA (Calbiochem). Actinomycin
D, cycloheximide, SB431542, U0126, SB202190,
SP600125, helenalin, and Bay11-7082 were from Biomol
(Plymouth Meeting, PA, USA). Bicinchoninic acid
(BCA) protein assay reagent was from Pierce (Rockford,
IL, USA). TGF-b1 was from R&D Systems (Minneapolis,
MN, USA). N-acetyl cysteine (NAC), enzymes, XTT
assay kit, and other chemicals were from Sigma
(St. Louis, MO, USA).
Rat brain astrocyte culture
RBA-1 cells were used throughout this study. This cell
line originated from a primary astrocyte culture of neo-
natal rat cerebrum and naturally developed through suc-
cessive cell passages [41]. Staining of RBA-1 with the
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(GFAP), showed nearly 95% positive staining. In this
study, the RBA-1 cells within 40 passages were used
that showed normal cellular morphological characteris-
tics and had steady growth and proliferation in the
monolayer system. Cells were cultured and treated as
previously described [40]. Primary astrocyte cultures
were prepared from the cortex of 6-day-old Sprague-
D a w l e yr a tp u p sa sp r e v i o u s l y described [9]. The purity
of primary astrocyte cultures was assessed with the
astrocyte-specific marker, GFAP, showing over 95%
GFAP-positive astrocytes. The cells were plated on 12-
well plates and 10-cm culture dishes for MMP gelatin
zymography and RT-PCR, respectively. The culture
medium was changed every 3 days.
MMP gelatin zymography
After TGF-b1 treatment, the culture medium was
collected, mixed with equal amounts of non-reduced
sample buffer, and electrophoresed on 10% SDS-polya-
crylamide gels containing 1 mg/ml gelatin as a protease
substrate. Following electrophoresis, gelatinolytic activity
was determined as previously described [40]. Mixed
human MMP-2 and MMP-9 standards (Chemicon,
Temecula, CA, USA) were used as positive controls.
Because cleaved MMPs were not reliably detectable,
only proform zymogens were quantified. When inhibi-
tors were used, they were added 1 h prior to the appli-
cation of TGF-b1. Treatment of RBA-1 cells with the
pharmacological inhibitors alone had no significant
effect on cell viability determined by an XTT assay (data
not shown).
Total RNA extraction and RT-PCR analysis
For RT-PCR analysis of MMP-9 mRNA expression, total
RNA was extracted from RBA-1 cells stimulated by
TGF-b1 as previously described [40]. The cDNA
obtained from 1 μg total RNA was used as a template
for PCR amplification. Oligonucleotide primers were
designed based on Genbank entries for rat MMP-9 and
b-actin. The following primers were used for amplifica-
tion reaction: for MMP-9: 5’-AGTTTGGTGTCGCG-
GAGCAC-3’ (sense), 5’-TACATGAGCGCTTCCGG
CAC-3’ (anti-sense); for b-actin: 5’-GAACCCTAAGGC-
CAACCGTG-3’ (sense), 5’-TGGCATAGAGGTCTT-
TACGG-3’ (anti-sense). The PCR amplification was
performed in 30 cycles at 55°C, 30 s; 72°C, 1 min; 94°C,
30 s. PCR fragments were analyzed on 2% agarose 1X
TAE gel containing ethidium bromide and their size
was compared to a molecular weight markers. Amplifi-
cation of b-actin, a relatively invariant internal reference
RNA, was performed in parallel, and cDNA amounts
were standardized to equivalent b-actin mRNA levels.
These primer sets specifically recognize only the genes
of interest as indicated by amplification of a single band
of the expected size (754 bp for MMP-9 and 514 bp for
b-actin) and direct sequence analysis of the PCR
product.
Cell migration (wound healing) assay
RBA-1 cells were grown to confluence in 6 well plates
and starved with serum-free DMEM/F-12 medium for
24 h. The monolayer cells were manually scratched with
a pipette tip to create extended and definite scratches in
the center of the dishes with a bright and clear field.
The detached cells were removed by washing the cells
once with PBS. Serum-free DMEM/F-12 medium with
or without TGF-b1 was added to each dish as indicated
after pretreatment with the inhibitors for 1 h. Images of
migratory cells from the scratched boundary were
observed and acquired at 48 h with a digital camera and
a light microscope (Olympus, Japan). The images shown
represent one of three individual experiments.
Preparation of cell extracts and western blot analysis
Growth-arrested RBA-1 cells were incubated with TGF-
b1 at 37°C for the indicated time intervals. The cells
were washed with ice-cold PBS, scraped, and collected
by centrifugation at 45,000 × g for 1 h at 4°C to yield
the whole cell extract, as previously described [40]. Sam-
ples were denatured, subjected to SDS-PAGE using a
10% (w/v) running gel, and transferred to nitrocellulose
membrane. Membranes were incubated overnight using
an anti-phospho-ERK1/2, phospho-JNK1/2, phospho-
p65, or GAPDH antibody. Membranes were washed
with TTBS four times for 5 min each, incubated with a
1:2000 dilution of anti-rabbit horseradish peroxidase
antibody for 1 h. The immunoreactive bands were
detected by ECL reagents.
Measurement of intracellular ROS generation
The peroxide-sensitive fluorescent probe 2’,7’-dichloro-
fluorescein diacetate (DCF-DA) was used to assess the
generation of intracellular ROS [42] with minor modifi-
cations. RBA-1 cells in monolayers were incubated with
RPMI-1640 supplemented with 5 μMD C F - D Af o r4 5
min at 37°C. The supernatant was removed and replaced
with fresh RPMI-1640 media before stimulation with
TGF-b1. Relative fluorescence intensity was recorded
over time (3 to 60 minutes) by using a fluorescent plate
reader (Thermo, Appliskan) at an excitation wavelength
of 485 nm and emission was measured at a wavelength
of 530 nm.
Plasmid construction, transient transfection, and
promoter activity assays
The dominant negative plasmids encoding ERK1
(ΔERK1), ERK2 (ΔERK2), p38 (Δp38), and JNK (ΔJNK)
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Biological Chemistry, University of Michigan, MI), Dr. J.
Han (The Scripps Research Institute, La Jolla, CA,
USA), and C.C. Chen (Department of Pharmacology,
National Taiwan University, Taipei, Taiwan), respec-
tively. The rat MMP-9 promoter was constructed as
previously described [43] with some modifications. The
upstream region (-1280 to +108) of the rat MMP-9 pro-
moter was cloned into the pGL3-basic vector containing
the luciferase reporter system. Introduction of a double-
point mutation into the NF-B-binding site (B domain;
GGAATTCC to GGAATTGG) to generate pGL-MMP-
9-DB (mt-B-MMP-9) was performed using the
following (forward) primer: 5’-GGGTTGCCCCGTGGA-
ATTGGCCCAAATCCTGC-3’ (corresponding to a
region from -572 to -541). The underlined nucleotides
indicate the positions of substituted bases. All plasmids
were prepared by using QIAGEN plasmid DNA pre-
paration kits. The MMP-9 promoter reporter constructs
were transfected into RBA-1 cells using the Lipofetami-
ne™RNAiMAX reagent according to the instructions of
manufacture (Invitrogen, Carlsbad, CA). The transfec-
tion efficiency (~60%) was determined by transfection
with enhanced EGFP. To assess promoter activity, cells
were collected and disrupted by sonication in lysis buf-
fer (25 mM Tris-phosphate, pH 7.8, 2 mM EDTA, 1%
Triton X-100, and 10% glycerol). After centrifugation,
aliquots of the supernatants were tested for luciferase
activity using a luciferase assay system. Firefly luciferase
activities were standardized to b-galactosidase activity.
Analysis of data
All data were estimated using GraphPad Prism Program
(GraphPad, San Diego, CA, USA). Quantitative data
were analyzed by one-way ANOVA followed by Tukey’s
honestly significant difference tests between individual
groups. Data were expressed as mean ± SEM. A value of
P < 0.05 was considered significant.
Results
TGF-b1 induces de novo synthesis of MMP-9 and cell
migration in RBA-1 cells
To investigate the effects of TGF-b1 on MMP-9 expres-
sion, RBA-1 cells were treated with various concentra-
tions of TGF-b1 for the indicated time intervals. The
condition media were collected and analyzed by gelatin
zymography. As shown in Figure 1A, TGF-b1i n d u c e d
MMP-9 expression in a time- and concentration-depen-
dent manner. There was an apparent up-regulation
within 16 h and sustained over 24 h. In contrast, the
expression of MMP-2 was not significantly changed dur-
ing incubation with TGF-b1 (Figure 1A). To further
examine whether the increase of MMP-9 expression by
TGF-b1 resulted from the induction of MMP-9 mRNA
expression, a RT-PCR analysis was performed. The data
show that TGF-b1 time-dependently induced MMP-9
mRNA expression in RBA-1 cells (Figure 1B), whereas
the expression of a housekeeping gene b-actin (as an
internal control) mRNA was not changed. There was a
significant increase in MMP-9 mRNA within 4 h and
sustained over 24 h during the period of observation.
Moreover, to determine whether the TGF-b1-induced
MMP-9 expression is dependent on de novo protein
synthesis, the cells were exposed to TGF-b1i nt h e
absence or presence of actinomycin D (Act. D) or cyclo-
heximide (CHI) at a dose known to inhibit transcription
or protein synthesis [44], respectively. The results show
that TGF-b1-induced MMP-9 expression was signifi-
cantly attenuated by pretreatment with either Act. D
(Figure 1C, upper panel) or CHI (Figure 1C, lower
panel) in a concentration-dependent manner. Moreover,
TGF-b1-induced MMP-9 mRNA accumulation was atte-
nuated by pretreatment with Act.D but not with CHI
(Figure 1D). Moreover, to demonstrate the functional
activity of MMP-9 expression induced by TGF-b1, we
evaluated in vitro cell migration of RBA-1 by a cell
migration assay. After 48 h of TGF-b1 incubation, the
images show that TGF-b1-enhanced cell migration was
blocked by pretreatment with the inhibitor of MMP-2/9
activity (2/9i) (Figure 1E), suggesting that up-regulation
of MMP-9 and its activity are required for enhancing
RBA-1 cell migration induced by TGF-b1.
TGF-b1 induces MMP-9 expression and cell migration via
a TGF-b type I receptor
SB431542, a selective inhibitor of TGF-b Type I recep-
tor (TGF-bRI), has been shown to abrogate TGF-b1-
mediated expression of several genes in different cell
types [45-47]. Thus, we examined whether TGF-b1
induced MMP-9 expression via TGF-bRI, a selective
TGF-bRI antagonist SB431542 was used for this pur-
pose. The data reveal that blockade of TGF-bRI by
SB431542 attenuated both TGF-b1-induced MMP-9
protein (Figure 2A) and mRNA (Figure 2B) expression.
Moreover, the involvement of TGF-bRI in TGF-b1-
induced cell migration was characterized by a cell
migration assay. The image data show that pretreatment
with SB431542 significantly attenuated TGF-b1-
enhanced cell migration (Figure 2C). These results
demonstrate that TGF-bRI-mediated MMP-9 induction
is essential for enhancing RBA-1 cell migration.
TGF-b1-induced MMP-9 expression is mediated through
ERK1/2
Accumulating evidence suggests that activation of
MAPK family, including ERK1/2, JNK1/2, and p38
MAPK, by TGF-b1 modulates cellular functions of dif-
ferent cell types in CNS [48,49]. First, to investigate the
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in RBA-1, cells were pretreated with an inhibitor of
MEK1/2, an upstream kinase of ERK1/2, U0126 for 1 h
and then incubated with TGF-b1 for 16 h. As shown in
Figure 3A, pretreatment with U0126 significantly inhib-
ited TGF-b1-induced MMP-9 expression in a concentra-
tion-dependent manner. Moreover, pretreatment with
U0126 (10 μM) also blocked TGF-b1-induced MMP-9
mRNA accumulation (Figure 3B). To determine whether
ERK1/2 phosphorylation was necessary for the induction
of MMP-9 expression in response to TGF-b1, activation
of ERK1/2 was assayed using an antibody specific for
the phosphorylated form of ERK1/2. The data show that
TGF-b1 stimulated the phosphorylation of ERK1/2 in a
time-dependent manner with a maximal response
obtained within 10 min (Figure 3C). In addition,
Figure 1 TGF-b1 induces de novo synthesis of MMP-9 and cell migration in RBA-1 cells. (A) Time and concentration dependence of TGF-
b1-induced MMP-9 expression. Cells were incubated with various concentrations of TGF-b1 for the indicated time intervals. The conditioned
media were collected and analyzed by gelatin zymography. The levels of TGF-b1-induced MMP-9 expression were quantified (right panel). (B)
Cells were treated with TGF-b1 (15 ng/ml) for the indicated time intervals. Total RNA was collected and analyzed by RT-PCR. (C) Cells were
pretreated with actinomycin D (Act. D, upper panel) or cycloheximide (CHI, lower panel) for 1 h and then incubated with TGF-b1 for 16 h. (D)
Cells were pretreated with or without Act.D (1 μM) or CHI (1 μM) before exposure to TGF-b1 for 6 h. The conditioned media and total RNA were
collected and analyzed by gelatin zymography (C) and RT-PCR (D). (E) For cell migration, cells were plated on 6-well plates and grew to
confluence. Cells were manually scratched with a pipette tip, and then incubated with or without TGF-b1 (15 ng/ml) for 48 h after pretreatment
with MMP-2/9 inhibitor (2/9i, 3 μM) for 1 h. Phase contrast images of RBA-1 cells were taken at 48 h in response to TGF-b1. Data are expressed
as mean ± SEM (A) or mean (B, C, D) of three independent experiments (n = 3). *P < 0.05;
#P < 0.01, as compared with the cells exposed to
vehicle (A, B) or TGF-b1 (C, D) alone. The image represents one of three similar experiments (n = 3).
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SB431542 for 1 h before exposure to TGF-b1 for 16 h. The conditioned media were collected and analyzed by gelatin zymography. (B) Cells
were pretreated with SB431542 (10 μM) before exposure to TGF-b1 for 6 h. Total RNA was collected and analyzed by RT-PCR. (C) For cell
migration, cells were pretreated with SB431542 (10 μM) for 1 h and then incubated with TGF-b1 (15 ng/ml) for 48 h. Representative phase
contrast images are shown for 48 h (n = 3). Data are expressed as mean of at least three independent experiments (n = 3).
#P < 0.01, as
compared with the cells exposed to TGF-b1 alone. The figure represents one of three individual experiments.
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TGF-b1-stimulated ERK1/2 phosphorylation (Figure
3D). To further ensure the role of ERK1/2 in TGF-b1-
induced MMP-9 expression, cells were transfected with
dominant negative mutant of either ERK1 (ΔERK1) or
ERK2 (ΔERK2) and then incubated with TGF-b1f o r1 6
h. The data show that transfection with either ΔERK1
or ΔERK2 significantly attenuated TGF-b1-induced
MMP-9 expression (Figure 3E), indicating that ERK1/2
is involved in TGF-b1-induced MMP-9 expression in
RBA-1 cells.
JNK1/2, but not p38 MAPK, is involved in TGF-b1-induced
MMP-9 expression
Next, we investigated the roles of p38 MAPK and JNK1/
2 in TGF-b1-induced MMP-9 expression in RBA-1, cells
Figure 3 Involvement of ERK1/2 in TGF-b1-induced MMP-9 expression in RBA-1 cells. (A) Cells were treated with TGF-b1 (15 ng/ml) for 16
h in the absence or presence of U0126. (B) Cells were pretreated with U0126 (10 mM) before exposure to TGF-b1 for 6 h. Total RNA was
collected and analyzed by RT-PCR. (C) Time dependence of TGF-b1-stimulated ERK1/2 phosphorylation, cells were incubated with TGF-b1 (15 ng/
ml) for the indicated time intevals. (D) Cells were treated with TGF-b1 (15 ng/ml) for 10 min in the absence or presence of U0126 (10 μM). The
whole cell lysates (C, D) were subjected to 10% SDS-PAGE and analyzed using an anti-phospho-ERK1/2 or anti-GAPDH (as an internal control)
antibody. (E) Cells were transfected with an empty vector (pcDNA3, as a control), a dominant negative mutant of ERK1 (ΔERK1) or ERK2 (ΔERK2)
for 24 h, and then exposed to TGF-b1 for 16 h. The conditioned media (A, E) were analyzed gelatin zymorgraphy. Data are expressed as mean ±
SEM (C) or mean (A, B, D, E) of at least three independent experiments (n = 3). *P < 0.05;
#P < 0.01, as compared with the cells exposed to
vehicle (C) or TGF-b1 (A, B, D, E) alone. The figure represents one of three individual experiments.
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(SB202190) or JNK1/2 (SP600125) for 1 h and then
incubated with TGF-b1f o r1 6h .T h ed a t as h o wt h a t
pretreatment with SB202190 had no significant effect on
TGF-b1-induced MMP-9 expression (Figure 4A).
Pretreatment with SP600125 significantly attenuated
TGF-b1-induced MMP-9 expression (Figure 4B). TGF-
b1-induced MMP-9 mRNA expression was also inhib-
ited by pretreatment with SP600125, but not SB202190
(Figure 4C), suggesting that TGF-b1-induced MMP-9
gene expression is mediated through JNK1/2, but not
p38 MAPK. To determine whether JNK1/2 phosphoryla-
tion was necessary for the induction of MMP-9 expres-
sion in response to TGF-b1, the activation of JNK1/2
was assayed using an antibody specific for the
phosphorylated form of JNK1/2. The data reveal that
TGF-b1 stimulated the phosphorylation of JNK1/2 in a
time-dependent manner with a maximal response
obtained within 4 h (Figure 4D). Pretreatment with
SP600125 (10 μM) significantly blocked TGF-b1-stimu-
lated JNK1/2 phosphorylation (Figure 4D). Similarly,
TGF-b1 stimulated p38 MAPK phosphorylation, which
was attenuated by pretreatment with SB202190 (10 μM)
(data not shown). To further ensure the role of JNK in
TGF-b1-induced MMP-9 expression, cells were trans-
fected with dominant negative mutant of either p38
MAPK (Δp38) or JNK (ΔJNK) and then incubated with
TGF-b1f o r1 6h .T h ed a t as h o wt h a tt r a n s f e c t i o nw i t h
ΔJNK markedly inhibited TGF-b1-induced MMP-9
expression, whereas transfection with Δp38 had no
apparent change in TGF-b1-induced MMP-9 expression
(Figure 4E). These results demonstrate that JNK1/2 is
also involved in TGF-b1-induced MMP-9 expression in
RBA-1 cells. For cell migration, pretreatment with either
U0126 or SP600125 significantly attenuated TGF-b1-
induced astrocytic migration (Figure 4F), indicating that
TGF-b1 induces cell migration via ERK1/2 and JNK
pathways in RBA-1 cells.
Involvement of ROS-dependent ERK1/2 and JNK1/2
pathways in TGF-b1-induced MMP-9 expression
Recently, several reports have demonstrated that
increasing ROS production contributes to expression of
several genes such as MMP-9 in different cell types
[50-52]. To examine whether ROS participated in TGF-
b1-induced MMP-9 expression, cells were pretreated
with N-acetyl cysteine (NAC, an ROS scavenger) for 1 h
and then incubated with TGF-b1 for 16 h. Our results
show that pretreatment with NAC reduced TGF-b1-
induced MMP-9 expression (Figure 5A) and its mRNA
accumulation (Figure 5B), implying that ROS may con-
tribute to induction of MMP-9 by TGF-b1i nR B A - 1
cells. To determine whether generation of ROS was
involved in TGF-b1-induced MMP-9 expression in
RBA-1 cells, a fluorescent probe DCF-DA was used to
determine the generation of ROS in these cells. RBA-1
cells were labeled with DCF-DA, incubated with TGF-
b1 for the indicated time intervals, and the fluorescence
intensity (relative DCF fluorescence) was measured at
485-nm excitation and 530-nm emission. The data
reveal that TGF-b1 stimulated intracellular ROS genera-
tion in a time-dependent manner with a maximal
response within 10 min and sustained over 60 min
(Figure 5C). Furthermore, TGF-b1-stimulated ROS gen-
eration was markedly attenuated by pretreatment with
NAC (Figure 5C), demonstrating that NAC is an
efficient ROS scavenger. Next, to determine whether
TGF-b1-induced MAPK phosphorylation occurs via a
ROS-dependent pathway, we pretreated cells with NAC
f o r1ha n dt h e ni n c u b a t e dt h e mw i t hT G F - b1f o r
10 min (for ERK1/2 phosphorylation) or 4 h (for JNK1/
2 phosphorylation). These results show that pretreat-
ment with NAC (100 μM) significantly reduced TGF-
b1-stimulated phosphorylation of ERK1/2 and JNK1/2
in RBA-1 cells (Figure 5D). In addition, the role of ROS
in TGF-b1-induced cell migration was assessed by a cell
migration assay. The imaging data show that TGF-b1-
induced cell migration is attenuated by pretreatment
with NAC (Figure 5E). Furthermore, to demonstrate the
direct role of ROS in MMP-9 up-regulation, cells were
directly exposed to various concentrations (0.1 and
1 mM) of H2O2 or to combination of 1 mM of H2O2 and
15 ng/ml of TGF-b1f o r2 4h .T h ed a t as h o wt h a te x p o -
sure of cells to H2O2 concentration-dependently induced
MMP-9 expression which was blocked by pretreatment
with NAC (Figure 5F), suggesting that ROS play a critical
role in up-regulation of MMP-9 in RBA-1 cells. These
results suggest that ROS-dependent ERK1/2 and JNK1/2
cascades may contribute to TGF-b1-induced MMP-9
expression and cell migration in RBA-1 cells.
NF-B is required for TGF-b1-induced MMP-9 expression
and cell migration in RBA-1 cells
Recent findings have suggested that NF-Bi saf u n d a -
mental transcription factor for induction of several
genes such as MMP-9 in astrocytes [9,53]. Moreover, as
shown in Figures 1C and 1D, we found that TGF-b1
induces MMP-9 expression at the transcriptional level.
The MMP-9 gene promoter with potential binding ele-
ments is required for recognition of transcription factors
including NF-B [37]. On the other hand, the NF-B
family is considered to be an essential regulator of both
cellular and inflammatory activities [54]. In astrocytes,
TGF-b1 has been shown to stimulate NF-B activation,
associated with astrocyte activation during CNS injury
[55]. Thus, we examined whether NF-Bw a sr e q u i r e d
for induction of MMP-9 by TGF-b1i nR B A - 1c e l l s .
First, cells were pretreated with the selective NF-B
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Page 8 of 17Figure 4 TGF-b1-induced MMP-9 expression is mediated through JNK1/2, but not p38 MAPK. Cells were treated with TGF-b1 (15 ng/ml)
for 16 h in the absence or presence of (A) SB202190 or (B) SP600125. (C) Cells were pretreated with SB202190 (SB, 10 μM) or SP600125 (SP, 10
μM) before exposure to TGF-b1 for 6 h. Total RNA was collected and analyzed by RT-PCR. (D) Time dependence of TGF-b1-stimulated JNK1/2
phosphorylation, cells were incubated with TGF-b1 (15 ng/ml) for the indicated times. Moreover, cells were treated with TGF-b1 for 4 h in the
presence of SP600125 (SP/4, 10 μM). (E) Cells were transfected with an empty vector (pcDNA3, as a control) or dominant negative mutant of
p38 MAPK (Δp38) or JNK (ΔJNK) for 24 h, and then exposed to TGF-b1 for 16 h. (F) For cell migration, cells were pretreated with U0126 (10 μM)
or SP600125 (10 μM) for 1 h and then incubated with TGF-b1 (15 ng/ml) for 48 h. The image is representative of three similar experiments (n =
3). The conditioned media (A, B, E) were analyzed gelatin zymorgraphy, and the whole cell lysates (D) were analyzed using an anti-phospho-
JNK1/2 or anti-GAPDH (as an internal control) antibody. Data are expressed as mean ± SEM (D) or mean (A, B, C, E) of at least three independent
experiments (n = 3). *P < 0.05;
#P < 0.01, as compared with the cells exposed to vehicle (D) or TGF-b1 (A, B, D, E) alone. The figure represents
one of three individual experiments.
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Page 9 of 17inhibitors, helenalin and Bay11-7082, which block acti-
vation of NF-B signaling [56], and then incubated with
TGF-b1 for 16 h. The zymographic data show that pre-
treatment with either helenalin or Bay11-7082 signifi-
cantly attenuated TGF-b1-induced MMP-9 expression
(Figure 6A) and mRNA accumulation (Figure 6B), sug-
gesting the involvement of NF-Bi nT G F - b1-induced
MMP-9 expression in RBA-1 cells. To further ensure
that activation of NF-B is involved in signaling stimu-
lated by TGF-b1, the phosphorylation of NF-Bp 6 5
was determined by western blot using an anti-phospho-
p65 NF-B antibody. As shown in Figure 6C, TGF-b1
stimulated phosphorylation of NF-B p65 in a time-
dependent manner, which was inhibited by pretreatment
Figure 5 ROS-dependent MAPK signaling is essential for TGF-b1-induced MMP-9 expression and cell migration in RBA-1 cells. (A) Cells
were treated with TGF-b1 (15 ng/ml) for 16 h in the absence or presence of N-acetyl cysteine (NAC). (B) Cells were pretreated with NAC (100
μM) before exposure to TGF-b1 for 6 h. The conditioned media and total RNA were collected and analyzed by gelatin zymography (A) and RT-
PCR (B). (C) Time dependence of TGF-b1-stimulated intracellular ROS generation, RBA-1 cells were incubated with the peroxide-sensitive
fluorescent probe DCF-DA (5 μM) for 45 min, followed by stimulation with TGF-b1 (15 ng/ml) for the indicated time intervals. Moreover, cells
were treated with TGF-b1 for 10 min in the presence of NAC (NAC/10, 100 μM). The DCF fluorescence intensity of cells was determined. (D) Cells
were pretreated with or without NAC (100 μM) for 1 h before exposure to TGF-b1 for 10 min (for ERK1/2) or 4 h (for JNK1/2). Whole cell lysates
were analyzed using an anti-phospho-ERK1/2, anti-phospho-JNK1/2, or anti-GAPDH (as an internal control) antibody. (E) For cell migration, cells
were pretreated with NAC (100 μM) for 1 h and then incubated with TGF-b1 (15 ng/ml) for 48 h. Representative phase contrast images are
shown for 48 h (n = 3). (F) Cells were pretreated with or without NAC (100 μM) for 1 h before exposure to H2O2 (0.1 or 1 μM) for 16 h or H2O2
(100 μM) and TGF-b1 for 16 h. Data are expressed as mean ± SEM (C) or mean (A, B, D, F) of three independent experiments (n = 3). *P < 0.05;
#P < 0.01, as compared with the cells exposed to vehicle (C) or TGF-b1 (A, B, D, F) alone. The figure represents one of three similar experiments.
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Page 10 of 17with U0126 (10 μM), SP600125 (10 μM), NAC (100
μM), or Bay11-7082 (1 μM) (Figure 6D), indicating that
TGF-b1-stimulated NF-B signaling is mediated through
ROS-dependent ERK1/2 and JNK1/2 cascades in RBA-1
cells. Furthermore, the cell migratory images show that
pretreatment with Bay11-7082 inhibited TGF-b1-
induced RBA-1 cell migration (Figure 6E). These results
demonstrate that NF-B is necessary for TGF-b1-
induced MMP-9 expression and cell migration in RBA-1
cells.
Figure 6 NF-B is involved in TGF-b1-induced MMP-9 expression and cell migration in RBA-1 cells. (A) Cells were treated with TGF-b1 (15
ng/ml) for 16 h in the absence or presence of helenalin or Bay11-7082. (B) Cells were pretreated with helenalin (HLN, 1 μM) or Bay11-7082 (Bay,
1 μM) before exposure to TGF-b1 for 6 h. The conditioned media and total RNA were collected and analyzed by gelatin zymography (A) and RT-
PCR (B). (C) Time dependence of TGF-b1-stimulated NF-B p65 phosphorylation, cells were incubated with TGF-b1 (15 ng/ml) for the indicated
time intervals. (D) Cells were pretreated with U0126 (U0, 10 μM), SP600125 (SP, 10 μM), NAC (100 μM), or Bay11-7082 (Bay, 1 μM) for 1 h before
exposure to TGF-b1 for 1 h. Whole cell lysates were analyzed by western blotting using an anti-phospho-NF-B-p65 antibody. (E) For cell
migration, cells were pretreated with Bay11-7082 (1 μM) for 1 h and then incubated with TGF-b1 (15 ng/ml) for 48 h. Representative phase
contrast images are shown for 48 h (n = 3). Data are expressed as mean ± SEM (C) or mean (A, B, D) of three independent experiments (n = 3).
*P < 0.05;
#P < 0.01, as compared with the cells exposed to vehicle (C) or TGF-b1 (A, B, D) alone. The figure represents one of three similar
experiments.
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Page 11 of 17Involvement of NF-B binding site in regulation of the rat
MMP-9 promoter by TGF-b1
We have found that TGF-b1 stimulates activation of
NF-B. Next, we examined whether the binding of NF-
B to its promoter binding element is essential for
TGF-b1-induced MMP-9 gene regulation. The rat
MMP-9 promoter luciferase reporter was constructed
and its activity was evaluated by a promoter-luciferase
activity assay. The rat MMP-9 promoter was con-
structed into a pGL3-basic vector containing a luciferase
reporter system (as illustrated in Figure 7A, upper part;
pGL-MMP-9-Luc), which possesses several putative
recognition elements for a variety of transcription fac-
tors including NF-Bf a m i l y .T h u s ,t od e t e r m i n et h e
effect of TGF-b1 on the MMP-9 promoter activity, cells
were transfected with a pGL-MMP-9-Luc construct and
then incubated with TGF-b1 for the indicated time
intervals. As shown in Figure 7A, TGF-b1 increased the
MMP-9 promoter activity in a time-dependent manner.
A maximal response was obtained within 16 h, which
was significantly inhibited by pretreatment with the
inhibitor of TGF-bRI (SB431542), MEK1/2 (U0126),
JNK1/2 (SP600125), NF-B (Bay11-7082), or an anti-
oxidant (NAC) (Figure 7B). To further ensure that NF-
B mediated TGF-b1-induced MMP-9 promoter activity
through binding to their regulatory elements within the
MMP-9 promoter region, wild-type (WT) MMP-9 pro-
moter, mutated by a single-point mutation of the B
binding site (mt-B-MMP-9), was constructed (as indi-
cated in Figure 7C, upper part). As shown in Figure 7C,
TGF-b1-stimulated MMP-9 promoter activity was sig-
nificantly attenuated in RBA-1 cells transfected with mt-
B-MMP-9, indicating that the B element is essential
for TGF-b1-induced MMP-9 promoter activity. These
results further confirm that TGF-b1 induces MMP-9
promoter activity via enhanced NF-B binding to the
B element of the MMP-9 promoter in RBA-1 cells.
Finally, using rat primary cultured astrocytes, we also
demonstrated that TGF-b1 induces MMP-9 expression
in a time-dependent manner (Figure 8A, upper panel).
The condition media were immunoprecipitated with an
anti-MMP-9 antibody and analyzed by western blot. As
shown in Figure 8A, TGF-b1 induced expression of
MMP-9 protein, but not MMP-2 protein, and release
into medium (lower panel), indicating that TGF-b1a l s o
induces MMP-9 protein expression and activation in rat
primary cultured astrocytes. In addition, pretreatment of
rat primary cultured astrocytes with various inhibitors
used in RBA-1 cells also significant attenuated TGF-b1-
induced MMP-9 expression (Figure 8B). These data
demonstrate that, as in RBA-1 cells, TGF-b1-induced
MMP-9 expression is also mediated through the same
signaling pathways in rat primary culture astrocytes.
Discussion
MMPs contribute to a wide range of biological activities
in several CNS diseases, such as stroke, Alzheimer’s dis-
ease, and malignant glioma [3]. Among MMPs, MMP-9
expression and activation have been shown to be predo-
minantly elevated by various brain injuries [4,6], sug-
gesting that MMP-9 may be a critical molecule in the
degradation of ECM and in the pathophysiology of
many brain diseases. Another gelatinase, gelatinase A
(MMP-2, 72 kDa), is constitutively expressed and its
expression is usually not inducible in several cell types
including brain cells. Moreover, TGF-b and related pep-
tides are simultaneously produced and released follow-
ing injury to the human CNS [48,57]. Despite an
obviously important role of TGF-b in brain trauma and
diseases, the processes by which TGF-b is implicated in
astrocytic functions are not completely understood. A
well-established rat astroglial cell line (RBA-1) is derived
from dissociated cultures of normal neonatal rat brain
tissues [41]. According to various analyses in previous
studies, the properties of RBA-1 cells are similar to
those of normal astrocytes [41]. Thus, we used a culture
model of RBA-1 cells to investigate the mechanisms
underlying TGF-b1-induced MMP-9 expression and cel-
lular functional responses. These results suggest that in
RBA-1 cells, activation of ROS-dependent ERK1/2 and
JNK1/2 linking to NF-B, mediated through a TGF-b
receptor, is essential for TGF-b1-induced MMP-9 gene
expression and cell migration. However, previous studies
have demonstrated that MMP-2 can be up-regulated by
some stimuli such as TGF-b, but usually participates in
development of cancer including growth, invasion, and
metastasis [25,58].
Abnormal regulation of MAPKs might be implicated
in several CNS disorders [8]. Moreover, TGF-b1h a s
been reported to act as a multifunctional factor through
activation of MAPK cascades in different cell types
[19,25,34]. In the present study, we found that ERK1/2
and JNK1/2 are required for MMP-9 expression, since
RBA-1 cells transfected with dominant negative ERK1
(ΔERK1), ERK2 (ΔERK2) or JNK (ΔJNK) plasmid led to
down-regulation of MMP-9 (Figures 3E and 4E). These
results are consistent with the MMP-9 expression and
secretion through ERK1/2 in rat cortical astrocytes
[8,40,59] and the induction of MMP-9 by oxidized low-
density lipoprotein via ERK1/2 and JNK1/2 pathways in
RBA-1 cells [10]. Our results are consistent with MMP-
9 expression through ERK1/2 in transformed keratino-
cytes [60]. Previously, many reports have indicated that
long-term activation of MAPKs may participate in regu-
lating some cellular functions such as gene expression
and cell survival [61,62]. Consistent with these reports,
our data show that TGF-b1 stimulated JNK1/2
Hsieh et al. Journal of Neuroinflammation 2010, 7:88
http://www.jneuroinflammation.com/content/7/1/88
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within 4 h (Figure 4D), suggesting that long-term phos-
phorylation of JNK1/2 by TGF-b1 may play a sustained
role in up-regulation of MMP-9 in RBA-1 cells. More-
over, we have also demonstrated that either p38 MAPK
inhibitor SB202190 or dominant negative mutant (Δp38)
have no effect on TGF-b1-induced MMP-9 expression
(Figures 4A, C, and 4E). However, recent reports have
also indicated that TGF-b-induced MMP-9 expression is
mediated through activation of p38 MAPK, but not
ERK1/2, in MCF10A human breast epithelial cells [63]
and in human glioblastoma cells [64]. The different
results may be due to diverse cell types and experimen-
tal conditions.
ROS have been shown to exert a key role in the phy-
siological functions and pathological processes [65-67].
In the brain, ROS also extend to the control of vascular
tone which is tightly modulated by metabolic activity
within neurons [68]. Moreover, increasing oxidative
stress (i.e. ROS production) by diverse stimuli can regu-
late the expression of inflammatory genes linked to
pathogenesis of human CNS disorders [65-69]. Recently,
increasing evidence attributes the cellular damage in
neurodegenerative disorders such as AD to oxidative
stress that is due to generation of free radicals impli-
cated in brain inflammatory disorders [30,32]. The
effects of TGF-b on ROS generation have been reported
to be involved in pathogenesis of tumor progression,
connective tissue degradation, and lung disease
[33,34,70]. In this study, we found that TGF-b1-induced
MMP-9 expression is mediated through ROS generation,
since pretreatment with ROS scavenger NAC signifi-
cantly attenuated TGF-b1-induced responses (Figures
5 A - C ) .T h er o l eo fR O Si nT G F - b1-induced ERK1/2
and JNK1/2 phosphorylation was further confirmed by
pretreatment with NAC (Figure 5D), suggesting that
ROS-dependent activation of ERK1/2 and JNK1/2 is
involved in TGF-b1-induced MMP-9 expression in
RBA-1 cells. Consistently, many reports have also shown
that MAPKs are the down-stream signaling molecules
regulated by ROS [34,70]. In addition, we demonstrated
that ROS participates in up-regulation of MMP-9 by
direct exposure of RBA-1 cells to H2O2 (Figure 5F).
Herein we are the first to establish that intracellular
ROS generation contributes to up-regulation of MMP-9
induced by TGF-b1 in RBA-1 cells.
NF-B is a well-known redox-regulated transcription
factor for expression of genes induced by diverse stress
signals, including mutagenic, oxidative, and hypoxic
stresses associated with physiological and pathological
events. Our results reveal that TGF-b1-induced MMP-9
expression via NF-Bp h o s p h o r y l a t i o n ,i sm e d i a t e d
through ROS-dependent ERK1/2 and JNK1/2 cascades
in RBA-1 cells (Figure 6). The requirement of NF-B
Figure 7 The ROS/MAPKs-dependent NF-B cascade is required
for TGF-b1-induced MMP-9 promoter activity. (A) Schematic
representation of a 5’-promoter regions of the rat MMP-9 gene
fused to the pGL-luciferase reporter gene (pGL-MMP-9-Luc). The
translational start site (+1) of the luciferase reporter gene is indicated
by an arrow. RBA-1 cells were transiently cotransfected with pGL-
MMP9-Luc and pGal encoding for b-galactosidase. After transfection,
cells were treated with TGF-b1 (15 ng/ml) for the indicated time
intervals. (B) Cells were pretreated with SB431542 (SB43, 10 μM),
NAC (100 μM), U0126 (10 μM), SP600125 (SP, 10 μM), or Bay11-7082
(Bay, 1 μM) for 1 h, and then incubated with TGF-b1 for 16 h. (C)
Activation of wild-type (WT) and NF-B-point-mutated (mt-B)
MMP-9 promoter constructs by TGF-b1. Schematic representation of
the different MMP-9-luciferase constructs, either wild-type (WT) or
modified by single-point mutation of the NF-B binding site (upper
panel). After overnight cotransfection and incubation with TGF-b1
for 16 h, promoter activities of different MMP-9-promoter constructs
were measured as relative MMP-9 promoter activity to b-
galactosidase. The relative increase in MMP-9 promoter activity
induced by TGF-b1 normalized to that of un-stimulated cells is
indicated as fold increase. Data are expressed as mean ± SEM of at
least three independent experiments (n = 3). *P < 0.05;
#P < 0.01, as
compared with the cells exposed to vehicle (A) or TGF-b1 (B, C)
alone.
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Page 13 of 17Figure 8 TGF-b1 induces MMP-9 expression and activation in the rat primary cultured astrocytes. (A) Time dependence of TGF-b1-
induced MMP-9 expression and activation. Cells were treated with TGF-b1 (15 ng/ml) for the indicated time intervals. The conditioned media
were collected and analyzed MMP-9 activity by gelatin zymography (upper panel). For MMP-9 protein level, conditioned media were
immunoprecipitated with an anti-MMP-9 antibody and analyzed by western blot (lower panel). (B) Cells were pretreated with SB431542 (SB43, 10
μM), NAC (100 μM), U0126 (10 μM), SB202190 (SB20, 10 μM), SP600125 (SP, 10 μM), or Bay11-7082 (Bay, 1 μM) for 1 h, and then treated with
TGF-b1 for 24 h. (C) Schematic pathway for TGF-b1-induced ROS-dependent MMP-9 expression and cell migration in RBA-1 cells. Each solid line
and arrow represents a step in an activating pathway. TGF-b1 induces MMP-9 expression via TGF-b receptor, ROS-dependent activation of ERK1/
2 and JNK1/2, and transcription factor NF-B pathway, which results in the promotion of cell migration in RBA-1 cells.
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Page 14 of 17signaling for MMP-9 induction has been confirmed by
in vitro and in vivo studies [40,53], which demonstrate a
relationship between MMP-9 expression and enhancing
cell motility [9,10] and tumor invasion [53]. In RBA-1
cells and human U87 astrocytoma cells, ERK1/2 has
been suggested to be necessary for NF-B activation
[40,71]. In addition, accumulating evidence also indi-
cates that TGF-b1-triggered urokinase up-regulation
and promotion of invasion is mediated through an
ERK1/2-dependent, but not p38 MAPK, activation of
NF-B in human ovarian cancer cells [72]. Our previous
study of RBA-1 cells has indicated that up-regulation of
MMP-9 by BK is mediated through an ERK1/2-depen-
dent NF-B pathway [40]. Recently, the JNK/NF-B
cascade has also been shown to participate in TGF-b1-
induced MMP-9 expression in corneal epithelial cells
[36]. These data imply that different MAPK members
are differentially involved in NF-B activation in various
cell types. These studies are consistent with our pre-
sented results in RBA-1 cells challenged with TGF-b1.
Cell migration is essential for the organization and
m a i n t e n a n c eo ft i s s u ei n t e g r i t ya n dp l a y sar o l ei n
embryonic development, wound healing, inflammation,
and invasiveness through ECM [73,74]. It has been
reported that ROS, MAPKs, and NF-B are involved in
MMP-9 up-regulation, which is crucial for regulating
cell motility in different cell types [9,56,75,76]. In this
study, we demonstrated that TGF-b1-enhanced cell
migration is mediated through up-regulation of MMP-9
protein and activity (Figure 1E) via TGF-b receptor and
ROS-dependent NF-B cascade (Figures 2C, 5E, and
6E). Moreover, to rule out the possibility of cell prolif-
e r a t i o ni nT G F - b1-induced cell migration, hydroxyurea,
an inhibitor of DNA synthesis [77], was used to prevent
proliferation of astrocytes during the period of observa-
tion in the migration (wound healing) assay. Therefore,
these results suggest that up-regulation of MMP-9 by
TGF-b1 is essential for enhancing migration of RBA-1
cells.
Conclusion
In the study, we have demonstrated that TGF-b1
directly induces MMP-9 expression via TGF-b receptor,
ROS-dependent activation of ERK1/2 and JNK1/2, and
transcription factor NF-B pathway, which results in the
promotion of cell migration in RBA-1 cells. Based on
observations from the literature and on our findings,
Figure 8C depicts a model for the molecular mechan-
isms underlying TGF-b1-induced MMP-9 expression
and migration of RBA-1 cells. These findings imply that
TGF-b1 might play a critical role in the processes of
wound healing and scar formation after brain injuries
and diseases. Pharmacological approaches suggest that
targeting MMP-9 and their upstream signaling
components may yield useful therapeutic targets for the
treatment of brain injury, tumors, and inflammatory
diseases.
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